InNexus Biotechnology Inc. (TSX.V:IXS) (www.ixsbio.com)
and XERIS Pharmaceuticals, Inc. (www.xerispharma.com)
announced today a research collaboration in which the companies will
pursue development of a potential subcutaneous delivery of InNexus’
Dynamic Cross Linking (DXL™) antibodies using XERIS’ proprietary
formulation-injection technologies.
“We see a need for an improved delivery system for antibodies that
enables self injection of these important therapeutic agents, by
patients at home,” said John Kinzell, CEO of XERIS. “Our delivery system
addresses a number of major issues related to storing and administering
antibodies and is suitable for and could add value in both chronic and
acute therapies.”
Jeff Morhet, CEO of InNexus said, “We continue to demonstrate
applicability of our DXL technology to a variety of disease targets and
we are excited to work with XERIS to identify DXL antibodies which are
suitable for subcutaneous delivery to patients using XERIS
formulation-injection technology. Antibodies are the leading choice of
pharmaceutical companies for drug development and we will continue to
position InNexus and our technology to take advantage or the industry’s
growth. This collaboration is novel and showcases two dynamic
technologies.”
The World Vaccine Congress returns to Barcelona, Spain